Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Cbd good for eczema treatment

of in role perspective prostate cancer: Basic and cannabinoids The clinical applic potential science

STHSeroGaz1
19.05.2018

Content:

  • of in role perspective prostate cancer: Basic and cannabinoids The clinical applic potential science
  • Cancer Center
  • Debbie's Articles
  • The role of cannabinoids in prostate cancer: Basic science perspective and potential It would be of interest to conduct clinical studies utilizing cannabinoids for possible role of cannabis and cannabinoids in the subject of prostate cancer. Request PDF on ResearchGate | The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applic.. Read Article. Read Article. Share This Article. Facebook .

    of in role perspective prostate cancer: Basic and cannabinoids The clinical applic potential science

    The Prostate 56 , 1— Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat.

    Cancer , — Proapoptotic effect of endocannabinoids in prostate cancer cells. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.

    Oncogene 30 , — The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.

    If you have information that this prescription advice is inaccurate, incomplete or outdated please contact us here. Home Education Introduction to cannabis-based medicine What are cannabinoids? This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.

    Metabolic Reprogramming to Improve Immunotherapy R The overall goal of this funding opportunity announcement FOA is to encourage R01 grant applications to a generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, b determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and c then use this information to manipulate reprogram the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

    The intent of this Funding Opportunity Announcement FOA is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.

    The overall goal of this funding opportunity announcement FOA is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat LTR and non-LTR retroelements, in cancer.

    Similarly, how human endogenous viruses HERVs affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

    As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot Phase I and II cancer imaging clinical trials, including patient monitoring and laboratory studies. This Funding Opportunity Announcement FOA encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer.

    This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles. Specifically, this FOA is intended to stimulate research aimed at 1 testing new theories and conceptual frameworks; 2 developing and evaluating novel strategies to improve cancer-related health behaviors; 3 investigating multi-level and multi-behavioral approaches; and 4 utilizing innovative research designs, methodologies, and technologies.

    Research can involve any aspect of the cancer continuum and any phase of the translational spectrum. The purpose of this funding opportunity announcement FOA is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers.

    Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy.

    Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied.

    The purpose of this Funding Opportunity Announcement FOA is to establish one or two centers that can rapidly generate high quality whole genome sequence and variant data from a large number of human specimens representing two types of pediatric conditions - childhood cancers and structural birth defects. All sequence data generated under this FOA will be re-processed and harmonized by the Gabriella Miller Kids First Pediatric Data Resource Center Kids First DRC , which is also charged with building a public-facing, web-based portal that will allow researchers to search, access, aggregate, analyze, and share annotated genomic sequence, variant, and phenotypic datasets.

    Together these resources will promote comprehensive and cross-cutting research and collaboration within the pediatric research community.

    The objective of the National Cancer Institute NCI Outstanding Investigator Award OIA is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques.

    It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

    This funding opportunity announcement FOA encourages applications for research in cancer control and population sciences.

    The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. The purpose of this Funding Opportunity Announcement FOA is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.

    Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation alemondand progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

    This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

    This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities.

    In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies such as R01 projects of the biology of cancer health disparities. The purpose of this Funding Opportunity Announcement FOA is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging QI methods are optimized to improve the quality of imaging results for co-clinical trials.

    The scientific goals of this FOA are to: Co-clinical trials are defined in this FOA as investigations in patients and in parallel or sequentially in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions.

    Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

    The CSBC initiative aims to address challenges in cancer research through the use of experimental biology or population science combined with in silico modeling, multi-dimensional data analysis, and systems engineering. This Funding Opportunity Announcement FOA invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment.

    CSBC Research Projects proposed in response to this FOA must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

    Clinical Trials Not Allowed for due dates on or after January 25, Only accepting applications that do not propose clinical trials. The overarching purpose of this Funding Opportunity Announcement FOA is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies.

    The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations. The institutions in each partnership are expected to work collaboratively to: This Funding Opportunity Announcement FOA encourages applications for short-term mentored career development K18 awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.

    This Funding Opportunity Announcement FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial.

    Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA FOA.

    Applications for administrative supplements are considered prior approval requests as described in Section 8. The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

    To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

    To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. The purpose of this Funding Opportunity Announcement FOA is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

    The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

    The intent of this FOA is two-fold: This Funding Opportunity Announcement FOA encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

    The purpose of this Funding Opportunity Announcement FOA is to inform the scientific community of the pain research interests of the various Institutes and Centers ICs at the National Institutes of Health NIH and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences.

    Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved.

    Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards K08 program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.

    This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Methodology and Measurement in the Behavioral and Social Sciences. The purpose of this Funding Opportunity Announcement FOA is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.

    The participating NIH Institutes and Centers ICs encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. The purpose of the NCI Mentored Research Scientist Development Award K01 is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences.

    This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development.

    Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA. This funding opportunity announcement FOA supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

    Integrating Individual and Group Level Evidence. To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement FOA is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

    Administrative supplements must support work within the scope of the original project. Research training programs will incorporate didactic, research, and career development elements to prepare individuals for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program T35 exclusively reserved for predoctoral, short-term research training.

    Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use ATOD. This FOA encourages applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits.

    Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years Phase I; R21 for protocol development, target identification and studies to confirm target engagement i. The National Institutes of Health NIH is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups.

    Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement FOA focuses on sexual and gender minority SGM populations, including lesbian, gay, bisexual, transgender, and intersex populations.

    Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed. This Funding Opportunity Announcement FOA supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

    This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

    The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Society of Urologic Oncology position statement: Redefining the management of hormone-refractory prostate carcinoma.

    Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX study. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Mechoulam R, Gaoni Y, Hashish The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. The first twelve thousand years.

    Plant, synthetic, and endogenous cannabinoids in medicine. Early medical use of cannabis. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Molecular characterization of a peripheral receptor for cannabinoids. The effect of chronically administered cannabis extract on the testicular function of mice. Depression of plasma testosterone levels after chronic intensive marihuana use. Enzymatic changes in the male reproductive organs by deltatetrahydrocannabinol.

    Chakravarty I, Ghosh JJ. Influence of cannabis and deltatetrahydrocannabinol on the biochemistry of the male reproductive organs. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.

    Inhibition of glioma growth in vivo by selective activation of the CB 2 cannabinoid receptor. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Androgen receptors and their biology.

    Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. A high cannabinoid CB 1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Localization of cannabinoid receptors in brain and periphery.

    The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Guindon J, Hohmann AG. The endocannabinoid system and pain. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

    Pharmacology of cannabinoid CB1 and CB2 receptors. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Cannabinoid CB 1 receptor expression in rat spinal cord. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study.

    Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55, Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects.

    Cannabinoid mechanisms of pain suppression. Pain modulation by release of the endogenous cannabinoid anandamide. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care. Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55, in experimental models of bone cancer pain and neuropathic pain.

    Acute and chronic administration of the cannabinoid receptor agonist CP 55, attenuates tumor-evoked hyperalgesia. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.

    The cannabinoid receptor agonist, WIN 55, , attenuates tumor-evoked hyperalgesia through peripheral mechanisms. The endocannabinoid nervous system: Unique opportunities for therapeutic intervention.

    Cancer Center

    Phase I clinical trials have this research will highlight potential side effects of cannabinoids and their .. The role of cannabinoids in prostate cancer: Basic · science perspective and potential clinical applications. Indian J. Cancer. Anticancer mechanisms of cannabinoids; Antitumor Activity of Plant Anti-tumoral action of cannabinoids on hepatocellular carcinoma- role of in prostate cancer- Basic science perspective and potential clinical application publication for phytocannabinoids in the treatment of cancer. Cannabinoids are the components in cannabis; some are commercially available to treat symptoms. Get detailed information in this clinician.

    Debbie's Articles



    Comments

    t1i2t3a4n5

    Phase I clinical trials have this research will highlight potential side effects of cannabinoids and their .. The role of cannabinoids in prostate cancer: Basic · science perspective and potential clinical applications. Indian J.

    guvd008

    Cancer. Anticancer mechanisms of cannabinoids; Antitumor Activity of Plant Anti-tumoral action of cannabinoids on hepatocellular carcinoma- role of in prostate cancer- Basic science perspective and potential clinical application publication for phytocannabinoids in the treatment of cancer.

    angel163

    Cannabinoids are the components in cannabis; some are commercially available to treat symptoms. Get detailed information in this clinician.

    Add Comment